Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definitive agreement for Jazz to acquire ...

Giuseppe Accogli became the Group CEO of Chiesi Pharmaceuticals in 2023. With a 25-year career in the med-tech industry, he ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are ...

JonesResearch downgraded Chimerix (CMRX) to Hold from Buy with an $8.55 price target after Jazz Pharmaceuticals (JAZZ) announced a deal to ...

From 2019-2023, North Carolina increased the number of life sciences business establishments by 43%. To learn more in the ...

U.S. equities traded higher Wednesday afternoon, near session highs, after Tuesday’s sharp selloff, which erased the S&P 500’s post-election gains. Autos, materials, builders, transports, and pharma ...

The stock makes the NASDAQ top percentage gainers list on acquisition news today, currently trading at $8.44, up 3.48, ...

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...